This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Cohen-Solal, A. Search for Related Content PubMed Articles by Cohen-Solal, A. Social Bookmarking                         What's this?

Management of Heart Failure Patients with Preserved Left Ventricular Ejection Fraction

University of Paris 7, Hospital Beaujon, Clichy, France, a.cohen.solal{at}wanadoo.fr

The diagnosis and management of chronic heart failure (CHF) with preserved left ventricular (LV) systolic function are problematic. Management strategies in current CHF guidelines are largely speculative, as to date few trials have studied such patients.The Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM)-Preserved study, the only study that has specifically recruited CHF patients with preserved left ventricular ejection fraction (LVEF), provides direct evidence that treatment with candesartan has substantial clinical benefits in this patient group, and this has been recognised in current guidelines for management of CHF. This treatment strategy warrants consideration in the management of these patients in the routine clinical setting. This case report discusses some of the issues in diagnosis and management of a patient with preserved LVEF.

Key Words: Heart failure • Preserved systolic function • Angiotensin receptor blockers

References

• Redfield MM, Jacobsen SJ, Burnett JC et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003;289:194-202.[Abstract/Free Full Text]
• Yusuf S., Pfeffer MA, Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777-81.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Swedberg K., Cleland J., Dargie H. et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). The Taskforce for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology H. Eur Heart J 2005;26:1115-40.[Free Full Text]
• European Study Group on diastolic heart failure. How to diagnose diastolic heart failure. Eur Heart J 1998;19:990-1003.[Free Full Text]
• Yusuf S., Gerstein H., Hoogwerf B. et al. Ramipril and the development of diabetes. JAMA 2001;286:1882-5.[Abstract/Free Full Text]
• Dahlöf B., Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 6, No. 2 suppl, S15-S16 (2005)
DOI: 10.1177/14703203050060020601


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Cohen-Solal, A. Search for Related Content PubMed Articles by Cohen-Solal, A. Social Bookmarking                         What's this?